Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Resul
Tibor HLAVATY | Senior gastroenterologist | MD, PhD, Assoc. Prof | Department of internal medicine V. | Research profile
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
European Crohn´s and Colitis Organisation - ECCO - The Council of National Representatives
Γεράσιμος Μάντζαρης: «Ύφεση νόσου με ασφαλή και αποτελεσματικά φάρμακα» - Hellenic Medical Review
John TRIANTAFILLIDIS | Inflammatory Bowel Disease Unit, IASO General Hospital, Athens, Greece | Associate Professor, University of Medicine and Pharmacy, Iasi, Romania | IASO Hospital, Athens, Athens | IASO | IBD unit
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
Palle BAGER | Clinical Nurse Specialist / Senior researcher / Associate Professor at Aarhus University | RN, MPH, PhD | Aarhus University Hospital, Århus | AUH | Department of Hepatology and Gastroenterology
iBDNEWS#1/14
Inflammatory Bowel Diseases
Julien KIRCHGESNER | Professor (Associate) | MD, PhD | Hôpital Saint-Antoine (Hôpitaux Universitaires Est Parisien), Paris | Service d'Hépato-Gastro-Entérologie - Nutrition
European Crohn´s and Colitis Organisation - ECCO - The Council of National Representatives
ECCO in Vienna was the Best Congress Ever!
PDF) Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease
ECCO in Vienna was the Best Congress Ever!
PDF) Budesonide is superior to mesalazine in maintaining disease remission for patients with steroid-dependent Crohn's disease | Gerassimos Mantzaris - Academia.edu
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
A continued story of success: Feeding science, digesting knowledge
PDF) P621 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn's disease patients: results from the EVOLVE study
European Crohn´s and Colitis Organisation - ECCO - Uncategorised
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. - Abstract - Europe PMC
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
WINTER
European Crohn´s and Colitis Organisation - ECCO - The Council of National Representatives
s of ECCO
Editorial_Board | Journal of Crohn's and Colitis | Oxford Academic
